Bensen Therapeutics Limited 06025726 true 2025-01-01 2025-12-31 2025-12-31 The principal activity of the company is is the holding of licences and associated patents for drugs being developed and undergoing clinical trials. Digita Accounts Production Advanced 6.30.9574.0 true A R Boyce true 06025726 2025-01-01 2025-12-31 06025726 2025-12-31 06025726 core:RetainedEarningsAccumulatedLosses 2025-12-31 06025726 core:ShareCapital 2025-12-31 06025726 core:SharePremium 2025-12-31 06025726 core:CurrentFinancialInstruments 2025-12-31 06025726 core:CurrentFinancialInstruments core:WithinOneYear 2025-12-31 06025726 core:OtherResidualIntangibleAssets 2025-12-31 06025726 bus:FRS102 2025-01-01 2025-12-31 06025726 bus:AuditExempt-NoAccountantsReport 2025-01-01 2025-12-31 06025726 bus:FullAccounts 2025-01-01 2025-12-31 06025726 bus:RegisteredOffice 2025-01-01 2025-12-31 06025726 bus:Director1 2025-01-01 2025-12-31 06025726 bus:EntityNoLongerTradingButTradedInPast 2025-01-01 2025-12-31 06025726 bus:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 06025726 core:IntangibleAssetsOtherThanGoodwill 2025-01-01 2025-12-31 06025726 1 2025-01-01 2025-12-31 06025726 countries:UnitedKingdom 2025-01-01 2025-12-31 06025726 2024-12-31 06025726 core:OtherResidualIntangibleAssets 2024-12-31 06025726 2024-12-31 06025726 core:RetainedEarningsAccumulatedLosses 2024-12-31 06025726 core:ShareCapital 2024-12-31 06025726 core:SharePremium 2024-12-31 06025726 core:CurrentFinancialInstruments 2024-12-31 06025726 core:CurrentFinancialInstruments core:WithinOneYear 2024-12-31 06025726 core:OtherResidualIntangibleAssets 2024-12-31 iso4217:GBP

Registration number: 06025726

Bensen Therapeutics Limited
Unaudited Filleted Financial Statements
for the Year Ended 31 December 2025

Bensen Therapeutics Limited

(Registration number: 06025726)
Balance Sheet as at 31 December 2025

| Note | 2025 £ | 2024 £
Fixed Assets |  |  |
Intangible assets | 3 | 253,800 | 253,800
Current assets |  |  |
Debtors | 4 | 1 | 1
Net assets |  | 253,801 | 253,801
Capital and Reserves |  |  |
Called up share capital | 5 | 101 | 101
Share premium reserve |  | 1,039,900 | 1,039,900
Retained Earnings |  | (786,200) | (786,200)
Shareholders' funds |  | 253,801 | 253,801

For the financial year ending 31 December 2025 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

Director's responsibilities:

• | The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
• | The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the director on 19 August 2026

......................................... A R Boyce Director

Bensen Therapeutics Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025

1 | General information

The company is a private company limited by share capital, incorporated in United Kingdom.

The address of its registered office is:
Ruffles Barn Brookside
Dalham
Newmarket
CB8 8TG
England

These financial statements were authorised for issue by the director on 19 August 2026.

2 | Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

The financial statements are presented in Sterling, which is the functional currency of the company.

Intangible assets

A revaluation model has been adopted based on the price paid for the shares in the holding company, Bensen Pharma Limited.

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Trade Debtors

Trade Debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.
Trade Debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Bensen Therapeutics Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

3 | Intangible assets

| Other intangible assets £ | Total £
Cost or valuation
At 1 January 2025 | 253,800 | 253,800
At 31 December 2025 | 253,800 | 253,800
Amortisation
Carrying amount
At 31 December 2025 | 253,800 | 253,800
At 31 December 2024 | 253,800 | 253,800

Impairment

Licence agreement
The intangible has been revalued to the price paid by a group of investors to develop the licence. The impairment loss is included in loss on financial assets.

4 | Debtors

Current | 2025 £ | 2024 £
Other debtors | 1 | 1
| 1 | 1

5 | Share capital

6 | Parent and ultimate parent undertaking

The company's immediate parent is Bensen Pharma Limited, incorporated in United Kingdom.